This contribution to immune suppression includes expression of immune checkpoint receptors like CTLA4 and PD1; by understanding how and where immune cells infiltrate the GBM microenvironment, we can better design treatment strategies which utilize ICIs to modulate the immune response to GBM tumors. Here, CTLA4 is linked to glioblastoma.